statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Agenus Inc. (Agenus) (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced results for the first quarter 2024. In a concurrent...

Agenus Reports First Quarter 2024 Results

Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) and Agenus Inc. (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced that the...

Ligand and Agenus Enter Into $100 Million Royalty Financing Agreement

Agenus Inc. (Agenus) (Nasdaq: AGEN), a leader in immunology-based therapies for cancer, received notice from NASDAQ on April 30, 2024, that the Company has regained compliance with the $1.00 minimum...

Agenus Regains Compliance with Nasdaq Minimum Bid Price Requirement

Agenus Inc. (Agenus) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced the Company will release its first quarter 2024 financial results...

Agenus to Provide First Quarter 2024 Financial Report and Corporate Update

The latest Phase 1 trial results of Agenus' botensilimab and balstilimab (BOT/BAL) combination therapy for metastatic CRC showcase promising clinical activity.

 Latest Ratings for AGEN...

Small-Cap Cancer Drug Developer Agenus' Highlights Encouraging Data From Colorectal Cancer, But Funding Concerns Loom

Agenus Inc. (NASDAQ: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced updated results from its Phase 1 clinical trial of BOT/BAL...

Agenus Announces Updated Phase 1 Data and Progress on BOT/BAL Development in Metastatic MSS Colorectal Cancer

Down 75%. Is Agenus Stock a Buy on the Dip...

Down 75%. Is Agenus Stock a Buy on the Dip?

Agenus Inc. (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced its stockholders have approved a one-for-twenty reverse stock...

Agenus Announces Reverse Stock Split of Common Stock

Agenus Inc. ( NASDAQ:AGEN ) shareholders that were waiting for something to happen have been dealt a blow with a 25...

Benign Growth For Agenus Inc. (NASDAQ:AGEN) Underpins Stock's 25% Plummet

StockNews.com upgraded shares of Agenus (NASDAQ:AGEN  Free Report) from a sell rating to a hold rating in a research report released on Sunday morning. Several other analysts have also issued...

Agenus (NASDAQ:AGEN) Upgraded to Hold at StockNews.com

Agenus, Inc. is a clinical-stage company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. Its product pipeline includes Balstilimab, Zalifrelimab, AGEN1181, AGEN1327, AGEN2373, AGENt-797 and AGEN1777. The company was founded by Garo H. Armen and Pramod K. Srivastava on March 31, 1994 and is headquartered in Lexington, MA.

Watchers	12,477
52-Wk Low	$4.78
52-Wk High	$42.60

Volume	831,166.00
52-Wk High	$42.60
52-Wk Low	$4.78

Period	Estimated	Reported	Surprise	Result
Q2'24	-$1.64	--	--	N/A
Q1'24	-$3.21	-$3.04	5.20%	BEAT
Q4'23	-$0.07	-$2.60	-3795.13%	MISSED
Q3'23	-$0.20	-$0.16	17.98%	BEAT
Q2'23	-$0.20	-$0.20	-2.56%	MISSED

AGEN Agenus Inc

About

Feed

News

Sentiment

Earnings

Fundamentals